United States: FDA Policy Aims To Smooth Generic Access To Samples Of Branded Drugs Subject To REMS Use Restrictions

In a draft guidance published December 4, 2014,1 the Food and Drug Administration (FDA) has attempted to remove, at least in part, a legal hurdle that had created challenges for generic drug companies: Acquiring the samples of brand name products required to perform the bioequivalence studies that are the linchpin to the generic drug approval process, as well as other analytical comparisons required for submission and approval of an Abbreviated New Drug Application (ANDA).

Background on REMS Programs and Their Impact on Generic Access to Innovator Product Samples

FDA long has recognized that some drugs that pose significant benefit/risk issues that might otherwise keep them from being approved could come to the market if additional measures beyond those provided in the product labeling were implemented relative to the drug posing the questionable benefit/risk ratio. Thus, with drugs such as Accutane® and Thalomid®, both of which can cause birth defects, the agency and the drugs' sponsors entered into arrangements where, as a condition of approval, the sponsors agreed to certain measures such as requiring women of childbearing years to agree to a pregnancy test before initiating treatment and to use birth control while taking the drugs.

Initially, these arrangements were not formally authorized by the Federal Food, Drug, and Cosmetic Act (FFDCA), but the sponsors agreed to the risk management provisions in order to secure approval. In 2007, Congress passed the Food and Drug Administration Amendments Act (the 2007 Amendments),2 which formally gave FDA the power to require innovative drug sponsors to initiate such programs – called Risk Evaluation and Mitigation Strategies (REMS) when the agency believed the risk/benefit ratio required such measures.

While many common REMS measures, such as medication guides and communication plans, do not directly impede access to the drug, the 2007 Amendments also gave FDA the power to require, in appropriate circumstances, that the innovator implement certain Elements To Assure Safe Use (ETASU)—such as the pregnancy test and contraception requirements already in place for Accutane®—for drugs that posed, in the agency's view, great enough risks that other measures were inadequate to ensure that the products could be safely used. In conjunction with giving FDA the power to require an ETASU, the 2007 Amendments also amended the FFDCA to render as misbranded any drug that was in violation of a REMS program measure such as ETASU requirements.3

An unintended consequence of approving a new drug application (NDA) for a drug with an ETASU program has been that, in many cases, generic firms seeking to acquire the samples of the NDA product found themselves unable to acquire the products from the holder of the NDA due to the ETASU restrictions. When pushed by generic firms to make samples of drugs subject to an ETASU available, holders of the approval for the brand NDA – referred to in the generic drug approval process as the "reference listed drug" (RLD) – have cited a number of grounds for why they should not be required to provide the samples to the generics, especially falling back on the assertion that they cannot legally provide the product under the REMS misbranding provisions of the FFDCA. Innovators also claimed that state tort law/products liability considerations also would expose them to liability by providing the samples to generic companies.

What the Draft Guidance Provides

In the draft guidance issued December 4, FDA created a mechanism for generic firms to request that FDA send a letter to the RLD holder of a drug subject to an ETASU. Before the letter can be sent to the RLD NDA holder, a generic firm will have to submit its bioequivalence protocol—including informed consent documents and other "informational materials"—reflecting the required ETASU elements to the agency for review. If FDA agrees that the protocol does contain the required ETASU measures, the generic firm will also have to provide FDA with a completed "disclosure authorization form" before FDA can issue the letter to the RLD holder.

In the letter to the RLD holder, FDA would inform the firm that the agency would not regard the innovator's provision of the samples of the RLD to the generic as a "violation of REMS." Specifically, the letter would state:

The Agency has determined that the protocols, informed consent documents, and informational materials contain safety protections comparable to those in the applicable REMS ETASU.

FDA will not consider it a violation of REMS for the RLD sponsor to provide the designated potential ANDA applicant (or its agent) a sufficient quantity of drug product to allow it to perform the testing necessary to support its ANDA and otherwise meet the requirements for ANDA approval.4

The guidance does not say how quickly FDA will respond to ANDA applicant requests for letters to the RLD holder of ETASU-restricted drugs. However, as the agency has a commitment to trying to secure the approval of "first generics" of previously sole source brand name products, FDA is likely to move fairly quickly on any requests made under the draft guidance.

Will the Draft Guidance Really Generate Access to Innovator Samples Subject to ETASU?

While the draft guidance would appear to remove one crucial element of innovator resistance to providing samples of the RLD to generic firms where an ETASU is in place, we expect that RLD holders will continue to resist making these products available. Indeed, several issues are not addressed by the draft guidance.

First, from an administrative law perspective, the draft guidance, even if it was in final form, would not have the force and effect of a law, as it is neither a regulation nor a statute. FDA makes clear that guidance documents are neither binding on FDA nor on industry. In addition, the guidance expresses, as a matter of policy, FDA's decision to, in effect, exercise its "enforcement discretion" to not hold an innovator company in violation of the law if it distributes a product in a manner that is not fully consistent with an ETASU in order to make samples available to a generic firm. We expect that some innovators may assert that they still would be technically in violation of the FFDCA by deviating from a REMS program and decline to make samples available under that rationale.

In addition, the draft guidance does not compel an innovator to provide the generic with samples. To date, this issue, which includes a focus on the non-FDA legal issue of whether a person can decline to do business with another person, has been the subject of litigation in several federal district courts. However, none of those lawsuits has resulted in a decision with any precedential value.

Finally, innovator companies contend that, even with FDA's blessing as reflected in the draft guidance, the innovators would expose themselves to liability under various state products liability and tort principles if they were to provide samples of a drug subject to an ETASU to a generic firm. While a generic firm could agree to indemnify and hold harmless an innovator under such circumstances, absent a court finding that the innovator must deal with the generic and provide samples, we would expect that innovators continue to decline to make samples available for as long as they can continue to assert a colorable argument from both a legal and policy perspective that they are not required to share their product with the generic industry.

Congress may eventually have to weigh in on this issue. Indeed, in September 2014, H.R. 5657, the Fair Access for Safety and Timely (FAST) Generics Act,5 was introduced by Reps. Steve Stivers (R-Ohio) and Peter Welch (D-Vt.). If enacted, the FAST Generics Act, among other things, actually would render misbranded any drug subject to a REMS if the NDA holder failed to supply samples of REMS-restricted RLD to an ANDA applicant or an applicant seeking to approval of a biosimilar under the Biosimilar Price Competition and Innovation Act of 2009. While it appears to enjoy bipartisan support, it remains to be seen how fast the FAST Generics Act moves through the halls of Congress.

If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Michael A. Swit, any member of the Pharmaceutical, Medical Device, Pharmacy and Food industry group or the attorney in the firm with whom you are regularly in contact.


1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425662.pdf.

2. Public Law 110-85 (September 27, 2007).

3. Section 502(y) of the FFDCA; codified at 21 USC § 352(y).

4. Draft Guidance, at 4.

5. See HR 5657, at https://www.congress.gov/bill/113th-congress/house-bill/5657/text.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions